Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$7.72 +6.8%	$9.66	$5.94 ▼ $37.38	$563.49M	2.21	1.25 million shs	8.59 million shs
BIIB Biogen	$123.53 +2.2%	$130.58	$110.04 ▼ $238.00	$18.08B	0.13	1.36 million shs	1.46 million shs
JANX Janux Therapeutics	$32.88 +2.6%	$29.80	$22.52 ▼ $71.71	$1.95B	3.27	847,327 shs	825,257 shs
VYGR Voyager Therapeutics	$3.64 +2.5%	$3.59	$2.75 ▼ $9.55	$201.34M	0.95	446,427 shs	296,256 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	+6.78%	-14.70%	+7.52%	-56.16%	-76.23%
BIIB Biogen	+2.15%	+3.95%	-5.93%	-14.17%	-42.84%
JANX Janux Therapeutics	+2.59%	+5.89%	+16.39%	-24.38%	-43.50%
VYGR Voyager Therapeutics	+2.54%	+4.90%	+6.74%	-33.21%	-56.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARVN Arvinas	3.3089 of 5 stars	4.3	2.0	0.0	1.8	2.5	1.3
BIIB Biogen	4.7033 of 5 stars	4.2	3.0	3.7	2.4	2.5	1.9
JANX Janux Therapeutics	3.0381 of 5 stars	3.5	2.0	0.0	2.9	5.0	0.0
VYGR Voyager Therapeutics	4.592 of 5 stars	4.6	1.0	4.6	2.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.63	Moderate Buy	$25.82	234.50% Upside
BIIB Biogen	2.38	Hold	$195.85	58.55% Upside
JANX Janux Therapeutics	3.09	Buy	$95.25	189.69% Upside
VYGR Voyager Therapeutics	3.11	Buy	$13.97	283.69% Upside

Current Analyst Ratings Breakdown

Latest ARVN, JANX, VYGR, and BIIB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/2/2025	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$26.00 ➝ $19.00
5/2/2025	ARVN Arvinas	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$12.00 ➝ $8.00
5/2/2025	ARVN Arvinas	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $16.00
5/2/2025	ARVN Arvinas	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$24.00 ➝ $14.00
5/2/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$81.00 ➝ $24.00
5/2/2025	ARVN Arvinas	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $16.00
5/2/2025	ARVN Arvinas	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/2/2025	ARVN Arvinas	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$52.00 ➝ $10.00
5/2/2025	BIIB Biogen	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$217.00 ➝ $205.00
5/2/2025	BIIB Biogen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$265.00 ➝ $220.00
5/2/2025	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$241.00 ➝ $187.00

(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$426.90M	1.32	N/A	N/A	$8.17 per share	0.94
BIIB Biogen	$9.68B	1.87	$20.28 per share	6.09	$114.71 per share	1.08
JANX Janux Therapeutics	$10.59M	183.74	N/A	N/A	$7.46 per share	4.41
VYGR Voyager Therapeutics	$80.00M	2.52	$2.58 per share	1.41	$5.37 per share	0.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$198.90M	-$0.66	N/A	N/A	N/A	-75.51%	-33.75%	-16.75%	N/A
BIIB Biogen	$1.63B	$11.19	11.04	7.48	1.51	16.87%	14.98%	8.76%	N/A
JANX Janux Therapeutics	-$58.29M	-$1.28	N/A	N/A	N/A	-463.91%	-10.47%	-9.86%	5/6/2025 (Estimated)
VYGR Voyager Therapeutics	$132.33M	-$1.13	5.13	N/A	N/A	15.80%	8.33%	6.15%	5/12/2025 (Estimated)

Latest ARVN, JANX, VYGR, and BIIB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	N/A	N/A	N/A	$13.55 million	N/A
5/6/2025	Q1 2025	JANX Janux Therapeutics	-$0.42	N/A	N/A	N/A	$0.59 million	N/A
5/1/2025	Q1 2025	ARVN Arvinas	-$0.93	$1.14	+$2.07	$1.14	$41.87 million	N/A
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
3/11/2025	Q4 2024	VYGR Voyager Therapeutics	-$0.35	-$0.59	-$0.24	-$0.59	$16.58 million	$4.39 million
2/27/2025	Q4 2024	JANX Janux Therapeutics	-$0.49	-$0.36	+$0.13	-$0.36	N/A	N/A
2/12/2025	Q4 2024	BIIB Biogen	$3.43	$3.44	+$0.01	$1.83	$2.42 billion	N/A
2/11/2025	Q4 2024	ARVN Arvinas	-$1.07	-$0.63	+$0.44	-$0.63	$62.79 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	4.64	4.64
BIIB Biogen	0.27	1.35	0.90
JANX Janux Therapeutics	N/A	38.80	38.80
VYGR Voyager Therapeutics	N/A	8.45	8.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
BIIB Biogen	87.93%
JANX Janux Therapeutics	75.39%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	5.23%
BIIB Biogen	0.16%
JANX Janux Therapeutics	29.40%
VYGR Voyager Therapeutics	4.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	72.99 million	65.18 million	Optionable
BIIB Biogen	8,720	146.38 million	146.14 million	Optionable
JANX Janux Therapeutics	30	59.17 million	37.05 million	Optionable
VYGR Voyager Therapeutics	100	55.31 million	52.15 million	Optionable

ARVN, JANX, VYGR, and BIIB Headlines

Recent News About These Companies

Institutional Shifts at Voyager Therapeutics Reflect Trends in NASDAQ Companies by Market Cap

May 2 at 8:37 PM | kalkinemedia.com

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

April 28, 2025 | globenewswire.com

Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) PT at $13.97

April 24, 2025 | americanbankingnews.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of "Buy" from Brokerages

April 22, 2025 | marketbeat.com

Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...

April 21, 2025 | finance.yahoo.com

FY2026 Earnings Forecast for VYGR Issued By Leerink Partnrs

April 20, 2025 | marketbeat.com

7 Analysts Assess Voyager Therapeutics: What You Need To Know

April 10, 2025 | nasdaq.com

Voyager Therapeutics (NASDAQ:VYGR) Receives "Buy" Rating from HC Wainwright

April 10, 2025 | marketbeat.com

Voyager updates on Alzheimer’s programs ‘compelling,’ says H.C. Wainwright

April 9, 2025 | markets.businessinsider.com

ADAR1 Capital Management LLC Acquires 86,158 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

April 9, 2025 | marketbeat.com

TD Cowen Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

April 8, 2025 | markets.businessinsider.com

2VYGR : 7 Analysts Assess Voyager Therapeutics: What You Need To Know

April 8, 2025 | benzinga.com

Raymond James Financial Inc. Takes Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

April 7, 2025 | marketbeat.com

Alfred Sandrock Sells 10,885 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock

April 6, 2025 | insidertrades.com

Insider Selling: Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Sells 10,885 Shares of Stock

April 6, 2025 | marketbeat.com

Prudential Financial Inc. Sells 82,100 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

April 6, 2025 | marketbeat.com

Voyager Therapeutics Presents Promising Tau-Targeting Gene Therapy And Antibody Data At AD/PD 2025

April 2, 2025 | nasdaq.com

Voyager Therapeutics, Inc.: Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD 2025

March 31, 2025 | finanznachrichten.de

Voyager Therapeutics announces new data from two preclinical programs

March 31, 2025 | markets.businessinsider.com

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

March 31, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

March 19, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN, JANX, VYGR, and BIIB Company Descriptions

Arvinas NASDAQ:ARVN

$7.72 +0.49 (+6.78%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$7.64 -0.08 (-0.97%)

As of 05/2/2025 07:59 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Biogen NASDAQ:BIIB

$123.53 +2.60 (+2.15%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$123.07 -0.46 (-0.37%)

As of 05/2/2025 07:55 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Janux Therapeutics NASDAQ:JANX

$32.88 +0.83 (+2.59%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$32.90 +0.02 (+0.08%)

As of 05/2/2025 06:22 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Voyager Therapeutics NASDAQ:VYGR

$3.64 +0.09 (+2.54%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$3.73 +0.09 (+2.50%)

As of 05/2/2025 07:02 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time